AstraZeneca Pharma India · NSE: ASTRAZEN · BSE: 506820
Q2 FY22 results · Jul–Sep 2021
AstraZeneca Pharma India reported revenue from operations of ₹197.71 crore (down 5.6% from Q2 FY21) and net profit of ₹11.95 crore (down 54.6% from Q2 FY21) for Q2 FY22 (Jul–Sep 2021), on a standalone basis.
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 197.71 | 209.48 | −5.6% | 175.40 | +12.7% |
| Other income | 2.84 | 4.71 | −39.7% | 2.90 | −1.9% |
| Total income | 200.55 | 214.19 | −6.4% | 178.30 | +12.5% |
| Profit before tax | 16.24 | 35.57 | −54.4% | 13.50 | +20.2% |
| Net profit for the period | 11.95 | 26.34 | −54.6% | 10.24 | +16.6% |
| EPS, basic (₹) | 4.78 | 10.54 | −54.6% | 4.10 | +16.6% |
| Net margin (%) | 6.0 | 12.6 | 5.8 |
Standalone
- Filed with BSE
- 10 Nov 2021, 17:27 IST
- Board meeting
- 09 Nov 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE